

Supplemental Digital Content 6: Predictors of Loss to Follow-up and Death among Adults Initiating Antiretroviral Therapy in Mozambique during 2004–2013 Estimated Using a Complete Case Analysis Approach (N=79,682)

		Original		LTFU		Mortality		
		n	AHR	(95% CI)	p	AHR	(95% CI)	p
Year of ART Initiation	2004	1,784	1.00	—	—	1.00	—	—
	2005	4,694	2.18	(1.44-3.29)	<0.001	1.21	(0.49-2.99)	0.677
	2006	12,634	3.22	(2.22-4.68)	<0.001	2.04	(1.16-3.61)	0.014
	2007	25,616	3.43	(2.37-4.96)	<0.001	1.91	(1.13-3.24)	0.015
	2008	26,704	3.92	(2.72-5.66)	<0.001	1.78	(1.06-2.98)	0.029
	2009	31,129	4.29	(2.97-6.22)	<0.001	1.85	(1.11-3.11)	0.019
	2010	37,449	5.13	(3.42-7.71)	<0.001	2.14	(1.26-3.65)	0.005
	2011	41,991	6.57	(4.25-10.17)	<0.001	2.19	(1.24-3.89)	0.007
	2012	58,892	8.76	(5.5-13.96)	<0.001	1.86	(1.06-3.28)	0.031
	2013	65,442	10.34	(6.24-17.13)	<0.001	1.50	(0.85-2.65)	0.164
Age Category	15-<20	10,485	1.00	—	—	1.00	—	—
	20-<25	38,533	0.83	(0.74-0.92)	0.001	1.11	(0.84-1.48)	0.454
	25-<30	60,910	0.67	(0.6-0.75)	<0.001	0.95	(0.72-1.26)	0.718
	30-<40	106,882	0.58	(0.51-0.66)	<0.001	0.88	(0.66-1.15)	0.347
	>=40	89,525	0.52	(0.45-0.6)	<0.001	1.00	(0.75-1.34)	0.994
Sex	Non-Pregnant Females	175,258	1.00	—	—	1.00	—	—
	Males	100,333	1.52	(1.42-1.63)	<0.001	2.29	(2.11-2.48)	0.000
	Pregnant Females	30,744	1.12	(1.01-1.25)	0.036	1.08	(0.84-1.38)	0.565
Marital Status	married	138,559	1.00	—	—	1.00	—	—
	single	99,540	1.08	(1.02-1.14)	0.005	1.15	(1.06-1.25)	0.001
	widowed/divorced	20,975	1.03	(0.97-1.09)	0.336	1.02	(0.9-1.16)	0.728
No of Biological Children	0 children	34,165	1.00	—	—	1.00	—	—
	1-2 children	99,969	0.94	(0.88-1)	0.061	0.88	(0.78-1)	0.049
	>=3 children	111,210	0.86	(0.8-0.92)	<0.001	0.85	(0.75-0.95)	0.006
Education level	none	28,606	1.00	—	—	1.00	—	—
	primary	143,102	0.93	(0.85-1.02)	0.124	0.99	(0.88-1.12)	0.844
	secondary	55,664	0.85	(0.75-0.96)	0.008	1.03	(0.9-1.2)	0.642
	university	3,454	1.05	(0.87-1.27)	0.602	1.24	(0.91-1.69)	0.165
Employment	employed	64,340	1.00	—	—	1.00	—	—
	Unemployed	170,683	1.05	(0.98-1.12)	0.152	0.99	(0.9-1.09)	0.793
	student	10,945	0.91	(0.83-0.99)	0.036	0.81	(0.66-1.01)	0.056
Referral Source	VCT	121,865	1.00	—	—	1.00	—	—
	PMTCT/EID	37,098	1.24	(1.15-1.34)	<0.001	0.89	(0.71-1.12)	0.330
	TB clinic	7,132	1.16	(1.02-1.32)	0.027	0.98	(0.77-1.25)	0.889
	HC referral	121,034	1.15	(1.04-1.27)	0.007	1.11	(0.98-1.26)	0.108
	other	19,061	1.06	(0.95-1.19)	0.289	1.17	(0.96-1.42)	0.121
WHO Stage	I	76,685	1.00	—	—	1.00	—	—
	II	52,260	0.97	(0.91-1.03)	0.287	1.09	(0.96-1.23)	0.195
	III	82,044	1.11	(1.02-1.21)	0.019	1.50	(1.3-1.73)	0.000
	IV	21,372	1.36	(1.24-1.48)	<0.001	2.76	(2.35-3.24)	0.000
Weight Categories	<45 kg	33,333	1.00	—	—	1.00	—	—
	45-60 kg	120,535	0.76	(0.72-0.81)	<0.001	0.52	(0.47-0.56)	0.000
	>60 kg	52,667	0.66	(0.6-0.73)	<0.001	0.33	(0.3-0.38)	0.000
CD4 Count Category	<50	28,226	1.00	—	—	1.00	—	—
	50-200	86,194	0.90	(0.85-0.96)	<0.001	0.61	(0.55-0.67)	0.000
	201-350	71,741	0.84	(0.79-0.9)	<0.001	0.44	(0.39-0.49)	0.000
	351-500	12,862	0.90	(0.84-0.97)	<0.001	0.47	(0.38-0.57)	0.000
	>500	9,660	1.06	(0.95-1.18)	0.283	0.59	(0.47-0.75)	0.000
CASG patient*	No	299,569	1.00	—	—	1.00	—	—
	Yes	6,766	0.69	(0.5-0.94)	0.021	0.96	(0.62-1.51)	0.873
Site Size**	1st quintile	5,820	1.00	—	—	1.00	—	—
	2nd quintile	18,384	1.16	(0.93-1.44)	0.188	0.77	(0.54-1.09)	0.135
	3rd quintile	38,393	0.99	(0.79-1.25)	0.931	0.62	(0.44-0.87)	0.005
	4th quintile	68,836	0.92	(0.71-1.2)	0.552	0.55	(0.39-0.78)	0.001
	5th quintile	174,902	0.85	(0.59-1.23)	0.391	0.41	(0.27-0.62)	0.000
Back-Bone	Zidovudine	166,840	1.00	—	—	1.00	—	—
	Stavudine	113,820	0.96	(0.89-1.04)	0.327	1.49	(1.3-1.71)	0.000
	Tenofovir	16,104	1.05	(0.79-1.38)	0.754	1.74	(1.02-2.96)	0.043
	Other	2,030	0.85	(0.59-1.22)	0.379	1.25	(0.78-2.02)	0.350
Third Drug	Nevirapine	248,958	1.00	—	—	1.00	—	—
	Efavirenz	42,903	1.06	(1-1.13)	0.052	0.93	(0.81-1.06)	0.259
	Protease Inhibitor	4,118	1.34	(1.08-1.67)	0.008	0.80	(0.48-1.31)	0.370
	Other	2,815	1.26	(1.03-1.55)	0.028	1.15	(0.73-1.82)	0.538

Abbreviations: PY, person-years; CI, confidence intervals; AHR, adjusted hazard ratio; WHO, World Health Organization; CASG, community antiretroviral therapy support group; VCT, voluntary counselling and testing; PMTCT/EID, prevention of mother-to-child transmission/early infant diagnosis; TB, tuberculosis; HC, health center.

*A separate binary variable indicating presence or absence of a CASG program at the facility was included in the multivariable model in case facilities selected for CASG scale-up were different to other facilities, but this variable was not a statistically significant predictor of either death or LTFU.

**The categorical variable indicating rate of enrollment at the site, coded into quintiles as a five-level variable, was included in the multivariable model but was not a statistically significant predictor of either death or LTFU.